Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know

Company Performance - Adma Biologics (ADMA) closed at $10.71, reflecting a +0.85% change from the previous session, outperforming the S&P 500's daily loss of 0.25% [1] - The stock has gained 10.28% over the past month, while the Medical sector gained 0.03% and the S&P 500 gained 3.59% [1] - Upcoming earnings per share (EPS) are projected at $0.08, indicating a 500% increase year-over-year, with revenue estimates at $87.03 million, up 44.75% from the prior-year quarter [1] Analyst Estimates - Recent changes to analyst estimates for Adma Biologics suggest a positive outlook on the company's business performance and profit potential [2] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks Adma Biologics at 3 (Hold) [2] - The Zacks Consensus EPS estimate has remained stagnant over the past month [2] Valuation and Industry Ranking - Adma Biologics has a Forward P/E ratio of 30.34, which is a premium compared to its industry's Forward P/E of 23.51 [3] - The Medical - Biomedical and Genetics industry ranks in the top 34% of all industries, with a current Zacks Industry Rank of 85 [3] - Research indicates that top-rated industries outperform the bottom half by a factor of 2 to 1 [3]